Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease.

Research output: Contribution to journalArticlepeer-review

Standard

Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. / Jia, W; Whitehead, Rebekah; Griffiths, L; Dawson, C; Bai, H; Waring, Rosemary; Ramsden, David; Hunter, JO; Cauchi, M; Bessant, C; Fowler, DP; Walton, C; Turner, C; Cole, Jeffrey.

In: FEMS Immunology and Medical Microbiology, Vol. 65, No. 1, 01.06.2012, p. 55-68.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{1bc523a5d06540d5a997735bf18bc378,
title = "Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease.",
abstract = "The relative abundance of different groups of sulphate reducing bacteria (SRB) in faecal DNA collected before and after therapy from patients suffering with Crohn's disease (CD), irritable bowel syndrome (IBS) or ulcerative colitis (UC) has been compared with that from healthy controls. Growth tests revealed that SRB were not more abundant in samples from CD patients before treatment than in the healthy control group. For most of the 128 samples available, these preliminary results were confirmed using degenerate PCR primers that amplify the dsrAB gene. However, some samples from CD patients before treatment contained a growth inhibitor that was absent from IBS or UC samples. In-depth sequencing of PCR-generated dsrB fragments revealed that the diversity detected was surprisingly low, with only 8 strains of SRB and the sulphite reducing bacterium, Bilophila wadsworthia, detected above the 0.1% threshold. The proportion of the two major species detected, B. wadsworthia and Desulfovibrio piger, was as high as 93.5% of the total SRB population in the healthy control group, and lower in all patient groups. Four previously undescribed species were found: it is impossible to predict whether they are sulphate or sulphite reducing bacteria. {\textcopyright} 2012 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.",
author = "W Jia and Rebekah Whitehead and L Griffiths and C Dawson and H Bai and Rosemary Waring and David Ramsden and JO Hunter and M Cauchi and C Bessant and DP Fowler and C Walton and C Turner and Jeffrey Cole",
year = "2012",
month = jun,
day = "1",
doi = "10.1111/j.1574-695X.2012.00935.x",
language = "English",
volume = "65",
pages = "55--68",
journal = "FEMS Immunology and Medical Microbiology",
issn = "0928-8244",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease.

AU - Jia, W

AU - Whitehead, Rebekah

AU - Griffiths, L

AU - Dawson, C

AU - Bai, H

AU - Waring, Rosemary

AU - Ramsden, David

AU - Hunter, JO

AU - Cauchi, M

AU - Bessant, C

AU - Fowler, DP

AU - Walton, C

AU - Turner, C

AU - Cole, Jeffrey

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The relative abundance of different groups of sulphate reducing bacteria (SRB) in faecal DNA collected before and after therapy from patients suffering with Crohn's disease (CD), irritable bowel syndrome (IBS) or ulcerative colitis (UC) has been compared with that from healthy controls. Growth tests revealed that SRB were not more abundant in samples from CD patients before treatment than in the healthy control group. For most of the 128 samples available, these preliminary results were confirmed using degenerate PCR primers that amplify the dsrAB gene. However, some samples from CD patients before treatment contained a growth inhibitor that was absent from IBS or UC samples. In-depth sequencing of PCR-generated dsrB fragments revealed that the diversity detected was surprisingly low, with only 8 strains of SRB and the sulphite reducing bacterium, Bilophila wadsworthia, detected above the 0.1% threshold. The proportion of the two major species detected, B. wadsworthia and Desulfovibrio piger, was as high as 93.5% of the total SRB population in the healthy control group, and lower in all patient groups. Four previously undescribed species were found: it is impossible to predict whether they are sulphate or sulphite reducing bacteria. © 2012 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

AB - The relative abundance of different groups of sulphate reducing bacteria (SRB) in faecal DNA collected before and after therapy from patients suffering with Crohn's disease (CD), irritable bowel syndrome (IBS) or ulcerative colitis (UC) has been compared with that from healthy controls. Growth tests revealed that SRB were not more abundant in samples from CD patients before treatment than in the healthy control group. For most of the 128 samples available, these preliminary results were confirmed using degenerate PCR primers that amplify the dsrAB gene. However, some samples from CD patients before treatment contained a growth inhibitor that was absent from IBS or UC samples. In-depth sequencing of PCR-generated dsrB fragments revealed that the diversity detected was surprisingly low, with only 8 strains of SRB and the sulphite reducing bacterium, Bilophila wadsworthia, detected above the 0.1% threshold. The proportion of the two major species detected, B. wadsworthia and Desulfovibrio piger, was as high as 93.5% of the total SRB population in the healthy control group, and lower in all patient groups. Four previously undescribed species were found: it is impossible to predict whether they are sulphate or sulphite reducing bacteria. © 2012 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

U2 - 10.1111/j.1574-695X.2012.00935.x

DO - 10.1111/j.1574-695X.2012.00935.x

M3 - Article

C2 - 22309113

VL - 65

SP - 55

EP - 68

JO - FEMS Immunology and Medical Microbiology

JF - FEMS Immunology and Medical Microbiology

SN - 0928-8244

IS - 1

ER -